A Phase 1 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3b) inhibitor

Clinical Trial Grant

Duke Scholars

Jessica Muller Sun

Principal Investigator Jessica Muller Sun Pediatrics, Hematology-Oncology

Administered By

Pediatrics, Hematology-Oncology

Awarded By

Actuate Therapeutics

Start Date

April 28, 2021

End Date

April 30, 2025

Administered By

Pediatrics, Hematology-Oncology

Awarded By

Actuate Therapeutics

Start Date

April 28, 2021

End Date

April 30, 2025